share_log

Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25

Moomoo 24/7 ·  Mar 12 08:06

Baird analyst Colleen Kusy maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $27 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment